Tamara Young

TL;DR: Evidence is provided that the proportional effect of SGLT2 inhibitors might attenuate with declining kidney function and there was clear, separate evidence of benefit for all eG FR subgroups, including for participants with a baseline eGFR 30-45 mL/min per 1·73 m2.

TL;DR: In participants with diabetes, the incidence of an eGFR <60 mL/min/1.73 m2 was high and older age, remoteness of residence, and the presence of various comorbid conditions were associated with higher incidence.

TL;DR: The infrastructure provided by the EXTEND45 Study will be useful for diabetes surveillance and examining other important clinical and epidemiological questions, and represents an efficient approach to assessing diabetes frequency and its risk factors in the community.

TL;DR: The EXTEND45 Study represents an unparalleled opportunity to perform extensive research into diseases of considerable public health and clinical importance and Strengths include the population-based nature of the cohort and the availability of longitudinal information on the complete disease pathway for affected individuals.

TL;DR: The effects of SGLT2 inhibition on eye disease in individuals with type 2 diabetes are probably null, although the available data cannot exclude small to moderate benefits or harms.